Oncolytics Biotech Inc (id:13739 ONC)
1.33 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 2:20:28 PM)
Exchange closed, opens in 1 day 19 hours
-4.32 CAD (-4.32%)
-3.62 CAD (-3.62%)
-18.90 CAD (-18.90%)
-11.33 CAD (-11.33%)
-42.67 CAD (-42.67%)
-5.00 CAD (-5.00%)
-82.10 CAD (-82.10%)
-97.51 CAD (-97.51%)
About Oncolytics Biotech Inc
Market Capitalization 108.37M
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
| Headquarters (address) |
322 11th Avenue SW Calgary T2R 0C5 AB Canada |
| Phone | 403 670 7377 |
| Website | https://www.oncolyticsbiotech.com |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ONC |
| Exchange | Toronto Stock Exchange |
| Currency | CAD |
| 52 week range | 1.15 - 2.32 |
| Market Capitalization | 108.37M |
| P/E trailing | -3.34 |
| P/E forward | -3.36 |
| Price/Book | 3.81 |
| Beta | 1.51 |
| EPS | -0.380 |
| EPS Canada (ID:82, base:722) | 1.84 |